Analysts Set Senti Biosciences, Inc. (NASDAQ:SNTI) Target Price at $9.00

Senti Biosciences, Inc. (NASDAQ:SNTI) has been given an average recommendation of “Moderate Buy” by the five brokerages that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $9.00.

SNTI has been the topic of several analyst reports. Chardan Capital increased their price objective on shares of Senti Biosciences from $12.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Leerink Partners began coverage on shares of Senti Biosciences in a report on Friday, November 21st. They set an “outperform” rating and a $6.00 target price for the company. Wall Street Zen upgraded shares of Senti Biosciences to a “sell” rating in a research report on Saturday, December 13th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a research note on Thursday, January 22nd.

Senti Biosciences Trading Up 2.9%

Shares of NASDAQ SNTI opened at $0.96 on Friday. The firm has a market capitalization of $25.37 million, a PE ratio of -0.29 and a beta of 2.12. Senti Biosciences has a 1 year low of $0.80 and a 1 year high of $5.10. The firm’s 50-day moving average is $0.99 and its 200-day moving average is $1.44.

Institutional Investors Weigh In On Senti Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Jane Street Group LLC acquired a new position in Senti Biosciences in the fourth quarter valued at about $40,000. Virtu Financial LLC bought a new stake in shares of Senti Biosciences in the 4th quarter valued at about $46,000. Citadel Advisors LLC bought a new stake in shares of Senti Biosciences in the 3rd quarter valued at about $117,000. Geode Capital Management LLC raised its position in shares of Senti Biosciences by 395.6% in the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after acquiring an additional 117,588 shares during the period. Finally, Armistice Capital LLC acquired a new stake in shares of Senti Biosciences in the 2nd quarter valued at approximately $1,883,000. Institutional investors own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.